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Summary points
• Current interest in differentiated models for HIV care has largely focused on the needs
of stable patients who are doing well on antiretroviral therapy. However, tailored ser-
vices are also needed for patients at the other end of the spectrum, those at high risk for
poor outcomes such as death and loss to follow-up.
• Clinical decision tools such as risk scores are needed to identify patients at high risk for
poor outcomes and to provide individualized risk assessment.
• Risk scores need to be simple to use, utilize routinely collected variables, be accurate in
predicting risk, and be generalizable across contexts.
Introduction
Over the past decade, the scale-up of HIV programs in resource-limited settings has been
remarkable, with over 17 million persons initiating lifesaving antiretroviral therapy (ART) by
the end of 2015 [1]. However, in order to reduce HIV-related morbidity and mortality and
decrease the number of new infections, it is critical to double the number of HIV-positive
patients on treatment by 2020 [2]. It is equally important for health outcomes among children
and adults on ART to be optimized [2,3]. To achieve these two goals—i.e., a massive increase
in the number of patients on ART as well as an enhancement in the quality of care—the global
health community has recognized the need for tailored HIV services to meet the unique needs
of different patient groups, often referred to as differentiated models of service delivery [4].
The World Health Organization (WHO) recommends differentiating patients into four
groups: those presenting with asymptomatic HIV infection at ART initiation, those initiating
ART with advanced HIV disease, those who are already on ART but are unstable on treatment,
and lastly those stable on ART with high adherence and a favorable clinical response [5]. How-
ever, to date, the focus has largely been on establishing differentiated service models for stable
patients with the goal of maintaining adherence and retention, enhancing patient satisfaction,
and increasing efficiencies in HIV programs, given the reality of overcrowded clinics that
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strain the capacity of the limited health workforce. Patient-managed community ART groups,
one example of a differentiated service delivery model for stable patients, require fewer clinical
assessments at health facilities. This in turn decompresses health facilities, relieves the work-
load of health care workers, and enables the patients to avoid transport costs, long wait times,
and time lost from family or work [6]. Eligibility criteria for these groups and similar less
intensive models of care are often based on prior performance—i.e., evidence of 6–12 months
of excellent clinic attendance with high adherence to treatment and, if available, evidence of
viral suppression [7,8]. Reported outcomes among such groups are impressive, with over 95%
of patients retained at 1 year [7,9].
The need for a priori identification of patients at high risk for poor
outcomes
Patients at high risk for poor outcomes, on the other hand, also require a service model that is
tailored to their unique needs. The first group of such patients consists of those at high risk for
early death after ART initiation. Adults with advanced HIV disease have been noted to have
mortality rates up to 5-fold higher in the first 6 months after treatment initiation compared
with after 1 year [10,11]. Mortality rates also remain high in the first year of treatment among
more recent cohorts with less advanced disease [12]. In a study of 19 cohorts with advanced
disease from sub-Saharan Africa, the mortality rate in the first 4 months after ART initiation
was 19.1 deaths per 100 person years (PY), decreasing to 1.3 deaths/100 PY beyond 1 year of
follow-up [11]. Similarly, in a multicountry study of over 37,000 HIV-infected children, the
mortality rate in the first 6 months was 9.1 deaths/100 PY versus 4.5 deaths/100 PY at 24
months [13]. This high early mortality is particularly evident among patients with HIV-related
tuberculosis, cryptococcal meningitis, or malnutrition [14–16]. For children, poor growth,
advanced disease, and young age are also predictive of early death [13,16].
The second group of patients at high risk for poor outcomes consists of those who default
early from care. Rates of loss to follow-up among adults and children are highest in the first
year after enrollment in care or initiation of treatment, with up to one-third of adult patients
noted to be lost to follow-up within the first 6 months [12,17,18]. Outcomes among those who
default from care are poor. In a meta-analysis of 28 studies conducted in sub-Saharan African
countries reporting outcomes among patients who were categorized as lost to follow-up with
unknown vital status and were traced in the community, the unreported mortality was 30%
(95% CI 21.1%–38.9%) [19]. Moreover, patients enrolled in care but who have yet to initiate
ART who experience more than a 12-month gap in their follow-up were found to re-present to
clinics with more advanced disease, which could have been prevented with more consistent
engagement in care [20]. Similarly, tracing studies among children who have been lost to fol-
low-up found that 16% of HIV-positive children and 29% of children with unknown HIV sta-
tus had died [21].
The evidence of poor outcomes among the two groups of patients described above demon-
strates that it is critically important to identify, a priori, these patients at the time of ART initia-
tion in order to prevent their loss to follow-up and to improve their clinical outcomes. Risk
scores and clinical decision tools have been used widely in clinical medicine to simplify and
standardize the identification of individuals at highest risk for a specific condition or health
outcome. For example, risk scores are used to predict patients at high risk for cardiovascular
disease [22] and pneumonia-related mortality [23] and to determine the need for hospitaliza-
tion among patients presenting with syncope [24]. In the context of HIV, risk scores have been
developed based on data from United States and European cohorts to assess short-term disease
progression in HIV-positive patients on ART, 1-year mortality, and viral suppression, but
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none have been developed based on information from HIV-positive patients in low- and mid-
dle-income countries [25–27].
Risk factors for poor outcomes in HIV are known, but individual
prediction tools are lacking
While multiple studies have identified individual risk factors associated with early death and
loss to follow-up among HIV-positive patients in resource-limited settings, work is needed to
translate univariable and multivariable models into validated and easy-to-use risk scores to
predict an individual’s risk of death and loss to follow-up after ART initiation [11,28–31]. In
contrast to the use of CD4+ count or WHO HIV disease staging to identify high-risk patients
for disease progression, a composite risk score may provide more specific information on the
magnitude of risk for each patient by integrating additional variables such as weight, history,
or the presence of a specific opportunistic infection and other parameters. Risk scores also
may identify patients who may not have advanced HIV disease but are at high risk of poor out-
comes because of a combination of socioeconomic or demographic variables such as limited
income, un- or underemployment, and a fragile social support network. For example, while
most providers are likely to intuit that a patient with a CD4+ count< 50 cells/mm3 or with
concurrent tuberculosis is at high risk for early mortality even after initiation of ART, there is
more ambiguity in determining the risk of early mortality for a patient with a CD4+ count of
250 cells/mm3 who lives alone and is unemployed.
Similar to the assessment of risk of early mortality, it is also critical to identify those at high
risk for loss to follow-up at the time of ART initiation. Among adults, factors associated with
loss to follow-up include male sex, adolescence and young adulthood, low income, and low
educational attainment [12,32]. For children, factors include age (<5 years as well as adoles-
cence), stigma from peers, family and community members, transport to clinic, and lack of
disclosure of HIV infection to the child [13,21,33]. There are other potential variables that may
be associated with loss to follow-up to increase the precision of a risk score such as distance to
clinic, prior clinic attendance, family support, and social stressors that could be incorporated
in deriving precise risk scores for loss to follow-up [34].
Ideally, risk scores for both early mortality and for loss to follow-up should be based on rou-
tinely collected clinical, laboratory, and demographic information in order to enable their uti-
lization across contexts. Fortunately, many HIV programs routinely collect common patient
variables such as age, sex, marital status, pregnancy status, weight, CD4+ count, WHO disease
stage, history, and current tuberculosis (TB) status among other parameters. Other potential
variables that can be easily obtained include education level, income, other comorbid diseases,
the presence of other household members with HIV, disclosure status, the presence of depres-
sion, and health facility characteristics such as the level of the facility (e.g., hospital versus
health center) and the distance of the health facility from the patient’s home.
A useful risk score must be distinguished by its potential for easy incorporation into clinical
practice, be reliable when applied by diverse cadres of health care providers, and be accurate in
predicting risks across settings [35]. It is important to avoid the complexity of some existing
risk scores that involve lengthy calculations and subtle clinical judgment, which is subject to
variation by provider. Once a risk score is proposed for identifying patients at high risk for
poor outcomes, it must then be externally validated to determine if its accuracy is preserved
when applied to a new population or setting and also over time. It is also important for the pro-
posed risk score to undergo formal impact analysis to evaluate if the score or prediction rule
influences physician behavior and patient outcomes, a step that is neglected for many pro-
posed prediction rules [36,37]. While a risk score may have excellent accuracy, it is only useful
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if it will be used by providers to change or direct their decisions. And finally, a fourth phase of
research is to evaluate if the rule has been actually implemented in practice [37].
Differentiated HIV service delivery for high-risk patients
While the development of simple risk scores to identify patients at high risk for poor outcomes
could be of substantial value, further efforts are needed to define interventions and care models
to minimize the risk of these poor outcomes. Interventions to mitigate early mortality after
ART initiation for patients with advanced HIV disease may include hospitalization of severely
ill patients, providing prophylaxis or pre-emptive therapy for opportunistic infections, and/or
more intensive clinical visit schedules. The WHO guidelines recommend for such patients the
rapid initiation of ART, screening and prompt treatment for coexisting TB or cryptococcus,
and provision of isoniazid preventive therapy, if indicated, as well as intensive follow-up for
patients with CD4+ count< 200 cells/mm3 or WHO stage III/IV disease [5]. The Reduction
of Early Mortality in HIV-Infected Adults and Children Starting Antiretroviral Therapy
(REALITY) trial conducted in Zimbabwe, Kenya, Malawi, and Uganda found that enhanced
prophylaxis at the time of ART initiation with ongoing cotrimoxazole prophylaxis, 12 weeks of
isoniazid/pyridoxine, 5 days of azithromycin, and a single dose of albendazole was associated
with a 25% reduction in early mortality among adults and children with CD4+ counts < 100
cells/mm3 [38]. The Reduction of Early Mortality among HIV-Infected Subjects Starting Anti-
retroviral Therapy (REMSTART) trial conducted in Tanzania and Zambia, in which patients
at clinics were assigned to a combination strategy that included screening for cryptococcal dis-
ease coupled with 4 weeks of home visits for monitoring response and ART adherence sup-
port, resulted in a 28% decrease in mortality when compared to the standard of care [39]. For
patients at high risk of loss to follow-up, structural and behavioral interventions such as accel-
erated ART initiation, phone messaging and texting for appointment reminders, tailored com-
munity support, and transport vouchers may be necessary to enhance retention in care [40].
Conclusions
Over the past decade, the scale-up of HIV services has saved millions of lives, but a substantial
proportion of patients continue to suffer poor health outcomes, particularly in the first year of
treatment. Clinical decision tools, including risk scores, are urgently needed to promptly iden-
tify such patients and to guide them to appropriately tailored services that offer them individ-
ual benefits while at the same time contributing to the efficient use of health system resources.
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